Opinion|Videos|November 21, 2025
Reinstating LDL-C Targets
Panelists discuss how reinstating LDL-C targets in quality programs could improve outcomes and accountability.
Advertisement
Episodes in this series
Panelists discuss how reinstating low-density lipoprotein cholesterol (LDL-C) targets could realign quality programs toward outcomes-driven care. Setting measurable goals encourages clinicians to intensify therapy and monitor progress.
They emphasize that outcomes-based incentives could harmonize payer and provider priorities, fostering accountability across systems. Restoring LDL-C targets may also reduce variability and close treatment gaps by making success measurable.
The discussion underscores that combining statin adherence metrics with LDL-C goal attainment could produce the most balanced and impactful framework.
Advertisement
Related to this article
Insmed’s once-daily TPIP prodrug shows sustained lung vasodilation in PAH and PH-ILD, improving walk distance, PALM outcomes, and quality of life.
ASPEN links green sputum to neutrophils and exacerbations; brensocatib (DPP1) lowers purulence, while meta-analysis supports fewer flare-ups in bronchiectasis.
Experts at CHEST 2026 urge pulmonologists to keep lung cancer in mind for younger patients who never smoked, to order screening and biomarker testing themselves, and to advocate for patients' access to care.
Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.
Satralizumab, a first-in-class IL-6 receptor inhibitor, was approved for adults with thyroid eye disease based on the phase 3 SatraGO program.
A higher PNR is associated with lower odds of MASLD and advanced liver fibrosis, but further studies are needed to validate findings.
Speakers at CHEST 2026 walked through the first CHEST guideline for non-CF adult bronchiectasis, including which preventive therapy to start first.
SaTScan detects an acute HCV outbreak cluster in California, showing the potential of automated surveillance, though real-time testing is needed.
Advertisement
Advertisement
Trending on AJMC
1
Patents, Rebates, and a Policy Patchwork Keep Inhalers Costly, Panelists Say
2
Administrative Burden Keeps Clinicians From Bedside: Amy Morris, MD
3
How Flatiron Health’s Network Chief Is Building the Future For (and With) Community Oncology Practices
4
International Panel Agrees on Framework for Tapering Psoriasis Biologics
5